ストックスクリーナーアプリを入手
17.08
0.59%
0.10
プレマーケット:
17.45
0.37
+2.17%
前日終値:
$16.98
開ける：
$16.92
24時間の取引高:
1.07M
Relative Volume:
0.56
時価総額：
$1.23B
収益：
-
当期純損益:
$-230.32M
株価収益率:
-4.8442
EPS:
-3.5259
ネットキャッシュフロー:
$-196.04M
1週間 パフォーマンス:
-8.37%
1か月 パフォーマンス:
-5.90%
6か月 パフォーマンス:
+84.05%
1年 パフォーマンス:
-50.89%
1日の値動き範囲:
$16.51
$17.39
1週間の範囲:
$15.77
$18.32
52週間の値動き範囲:
$5.95
$62.75
Moonlake Immunotherapeutics Stock (MLTX) Company Profile
Compare MLTX vs VRTX, REGN, ARGX, ALNY, INSM
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
MLTX
Moonlake Immunotherapeutics
|
17.08 | 1.23B | 0 | -230.32M | -196.04M | -3.5259 |
VRTX
Vertex Pharmaceuticals Inc
|
431.86 | 109.85B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
760.27 | 80.38B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
765.43 | 47.60B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
319.52 | 42.63B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
163.03 | 35.19B | 606.42M | -1.28B | -997.58M | -6.403 |
Moonlake Immunotherapeutics Stock (MLTX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-23 | アップグレード | Wolfe Research | Underperform → Outperform |
| 2026-03-19 | アップグレード | Rothschild & Co Redburn | Neutral → Buy |
| 2026-01-15 | ダウングレード | Goldman | Neutral → Sell |
| 2026-01-09 | アップグレード | BTIG Research | Neutral → Buy |
| 2025-11-03 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2025-10-02 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2025-10-01 | ダウングレード | Goldman | Buy → Neutral |
| 2025-09-30 | ダウングレード | Citigroup | Buy → Neutral |
| 2025-09-30 | ダウングレード | Wolfe Research | Outperform → Underperform |
| 2025-09-29 | ダウングレード | BTIG Research | Buy → Neutral |
| 2025-09-29 | ダウングレード | Jefferies | Buy → Hold |
| 2025-09-29 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-09-29 | ダウングレード | Stifel | Buy → Hold |
| 2025-07-28 | 開始されました | Rothschild & Co Redburn | Neutral |
| 2025-05-19 | アップグレード | Wolfe Research | Peer Perform → Outperform |
| 2025-03-18 | 開始されました | RBC Capital Mkts | Outperform |
| 2025-01-17 | アップグレード | Goldman | Neutral → Buy |
| 2024-11-05 | 再開されました | Wedbush | Outperform |
| 2024-08-26 | ダウングレード | Wolfe Research | Outperform → Peer Perform |
| 2024-06-25 | 開始されました | Oppenheimer | Outperform |
| 2024-04-02 | 開始されました | Goldman | Neutral |
| 2024-02-15 | 開始されました | Wolfe Research | Outperform |
| 2023-12-08 | 開始されました | Citigroup | Buy |
| 2023-11-02 | 開始されました | Stifel | Buy |
| 2023-09-14 | ダウングレード | Bryan Garnier | Buy → Neutral |
| 2023-08-31 | 開始されました | Needham | Buy |
| 2023-06-15 | 開始されました | Barclays | Equal Weight |
| 2023-05-01 | 開始されました | Guggenheim | Buy |
| 2023-03-22 | 開始されました | Wedbush | Outperform |
| 2023-03-09 | 開始されました | BTIG Research | Buy |
| 2023-02-14 | 開始されました | Cantor Fitzgerald | Overweight |
| 2023-02-02 | 開始されました | Bryan Garnier | Buy |
| 2022-11-11 | 開始されました | Jefferies | Buy |
| 2022-08-25 | 開始されました | SVB Leerink | Outperform |
| 2022-07-21 | 開始されました | H.C. Wainwright | Buy |
| 2022-07-07 | 開始されました | Cowen | Outperform |
すべてを表示
Moonlake Immunotherapeutics (MLTX) 最新ニュース
Biotech Fund BVF Trims MoonLake Stake, Sells $63M in Shares - The Motley Fool
BVF's departure from MoonLake suggests a shift towards high-beta rebalancing as institutions remain divided in their perspectives - Bitget
Biotech Fund BVF Trims MoonLake Stake, Sells $63M in Shares - The Motley Fool
MLTX SEC FilingsMoonLake Immunotherapeutics 10-K, 10-Q, 8-K Forms - stocktitan.net
MoonLake Immunotherapeutics (NASDAQ:MLTX) Receives Average Recommendation of "Hold" from Analysts - MarketBeat
How MoonLake’s Phase 3 Sonelokimab HiSCR75 Data in HS Could Shape MoonLake Immunotherapeutics (MLTX) Investors - simplywall.st
MoonLake Immunotherapeutics (MLTX) Stock Price, News, Quote & History - Yahoo! Finance Canada
How Investors Are Reacting To MoonLake Immunotherapeutics (MLTX) Long-Term Sonelokimab Data In Hidradenitis Suppurativa - finance.yahoo.com
Major Insider Move at MoonLake Immunotherapeutics Shakes Up Investor Sentiment - TipRanks
Bvf Partners P/Il Sells 3,750,000 Shares of MoonLake Immunotherapeutics (NASDAQ:MLTX) Stock - MarketBeat
BVF-linked MoonLake (MLTX) holder trims stake by 3.75M shares - stocktitan.net
MoonLake (MLTX) holder BVF sells shares but keeps 22.3% stake - stocktitan.net
MLTX Stock Jumps Overnight: Lead Skin Disease Drug Delivers Strong Phase 3 Gains With Majority Of Patients Improving - Stocktwits
MoonLake Immunotherapeutics (NASDAQ:MLTX) Trading Down 12.8%Here's Why - MarketBeat
MLTX stock garners retail attention on buyout speculation, positive skin condition trial data - msn.com
Form 144 | MoonLake Immunotherapeutics(MLTX.US) 10% Stockholder Proposes to Sell 63.49 Million in Common Stocks - Moomoo
Affiliate sale notice: 3,750,000 shares proposed (NASDAQ: MLTX) - stocktitan.net
MLTX Stock Garners Retail Attention On Buyout Speculation, Positive Skin Condition Trial Data - Stocktwits
MoonLake Immunotherapeutics Jumps 9.6% During the Day Amid Positive Developments and Analyst Rating Increases - Bitget
TD Cowen Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating - 富途牛牛
MoonLake Immunotherapeutics (NASDAQ:MLTX) Trading Up 8.7%Here's What Happened - MarketBeat
MoonLake’s lead asset shows durability in late-stage HS studies - finance.yahoo.com
Cantor Fitzgerald reiterates Moonlake stock rating on regulatory outlook By Investing.com - Investing.com India
Cantor Fitzgerald reiterates Moonlake stock rating on regulatory outlook - Investing.com
LifeSci Capital Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Maintains Target Price $33 - 富途牛牛
Assessing MoonLake Immunotherapeutics (MLTX) Valuation After A Premium Price To Book Multiple And Recent Share Moves - simplywall.st
Research Analysts Issue Forecasts for MLTX Q1 Earnings - MarketBeat
Precision Trading with Moonlake Immunotherapeutics (MLTX) Risk Zones - Stock Traders Daily
What's Going On With MoonLake Stock Monday?MoonLake (NASDAQ:MLTX) - Benzinga
MoonLake and Incyte progress HS prospects at AAD - The Pharma Letter
BTIG reiterates Moonlake stock rating on hidradenitis suppurativa data - uk.investing.com
BTIG reiterates Moonlake stock rating on hidradenitis suppurativa data By Investing.com - Investing.com South Africa
MoonLake Immunotherapeutics (NASDAQ:MLTX) Receives Buy Rating from BTIG Research - MarketBeat
H.C. Wainwright Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Maintains Target Price $40 - news.futunn.com
Wedbush Maintains MoonLake Immunotherapeutics(MLTX.US) With Buy Rating, Maintains Target Price $34 - 富途牛牛
MoonLake Reveals New Sonelokimab HS Phase 3 Trial Results - The Clinical Trial Vanguard
MLTX Bounces on Week 40 Trial Data—Is This a Setup for a Gamma Squeeze Before H2 2026 BLA Deadline? - Bitget
MoonLake Immunotherapeutics (MLTX) Is Up 6.5% After Strong Week 40 Sonelokimab HS Data Release – Has The Bull Case Changed? - simplywall.st
AAD26: MoonLake, Incyte highlight deepening responses in long-term HS readouts - FirstWord Pharma
MoonLake Immunotherapeutics announces results from Phase 3 VELA-1, VELA-2 trial - TipRanks
Sonelokimab Demonstrates High HiSCR100 Rates and Durable Responses in Hidradenitis Suppurativa - Dermatology Times
MoonLake Immunotherapeutics officially released the 40-week key data from the phase III clinical trial of its innovative drug Sonelokimab for the treatment of moderate to severe hidradenitis suppurativa at the 2026 American Academy of Dermatology (AAD) An - Bitget
MoonLake Immunotherapeutics Reports Positive Week 40 Results from Phase 3 VELA Trials of Sonelokimab in Moderate-to-Severe Hidradenitis Suppurativa - Quiver Quantitative
Skin disease trial shows 62% response at 40 weeks, no new safety signals - stocktitan.net
MoonLake Immunotherapeutics (MLTX) price target increased by 35.37% to 30.19 - MSN
Earnings Risk: What is the earnings history of MoonLake ImmunotherapeuticsQuarterly Trade Report & Low Drawdown Trading Strategies - baoquankhu1.vn
This Fund Bought $28 Million of a Beaten-Down Immunotherapy Stock Last Quarter. What Should Long-Term Investors Know? - AOL.com
Buy Signal: What analysts say about MoonLake Immunotherapeutics stock2026 Breakouts & Breakdowns & Weekly Setup with High ROI Potential - baoquankhu1.vn
Breakout Watch: What is the Moat Score of MoonLake Immunotherapeutics2026 Action & Fast Gaining Stock Reports - baoquankhu1.vn
MoonLake stock soars as biotech fund reloads, takeover chatter ignites - MSN
MoonLake surges 65% after InvestingPro Fair Value identifies opportunity By Investing.com - Investing.com Australia
Moonlake Immunotherapeutics (MLTX) 財務データ
収益
当期純利益
現金流量
EPS
0.47%
2.75%
大文字化:
|
ボリューム (24 時間):